Kevin Kalinsky

Also affiliated with Piedmont Cancer Institute, Sylvester Comprehensive Cancer Center, Winship Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1020

Top 20%

1.0DataRank

Top 20%43 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +50 more

Papers

Driven by 19 papers — median percentile 80. Top paper: “Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial”.

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Annals of Oncology(2020)10.1016/j.annonc.2020.09.004

N/A

5.0DataRank · unranked

145 citations

Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy +11 more

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer

Nature Cancer(2022)10.1038/s43018-022-00489-5

N/A

2.2DataRank · unranked

77 citations

Qingfei Pan, Codruța Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan +21 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1020

Top 20%

1.0DataRank

Top 20%43 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +50 more

Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-07172-y

N/A

0.957DataRank · unranked

24 citations

Shing Yip Lee, Cheng S. Leu, Bruce Levin, Meghna S. Trivedi, Katherine D. Crew +12 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma

European Journal of Nuclear Medicine and Molecular Imaging(2024)10.1007/s00259-024-06830-7

N/A

0.410DataRank · unranked

8 citations

Ismaheel O. Lawal, Saima Muzahir, Sarah Friend, Manali Bhave, Jane Meisel +8 more

Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center

Clinical Breast Cancer(2022)10.1016/j.clbc.2022.10.005

N/A

0DataRank · unranked

5 citations

Princess Ekpo, Manali Rupji, Jeffrey M. Switchenko, Mylin A. Torres, Kevin Kalinsky +2 more

A Tale of 3 Tracers

Clinical Nuclear Medicine(2022)10.1097/rlu.0000000000004385

N/A

0DataRank · unranked

3 citations

Omotayo A. Adediran, Saima Muzahir, Sarah Friend, Manali Ajay Bhave, Jane Meisel +10 more

Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3567

N/A

0DataRank · unranked

1 citations

Veena Singh, Shing Mirn Lee, David Cieremans, Andrew B. Lassman, Dawn L. Hershman +12 more

A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

JCO Precision Oncology(2023)10.1200/po.22.00532

N/A

0DataRank · unranked

16 citations

Taronish D. Dubash, Gabriela N. Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim +27 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520

N/A

0DataRank · unranked

2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00968

N/A

0DataRank · unranked

27 citations

Robyn D. Gartrell, Margueritta El Asmar, Shuobo Boboila, Thomas D. Hart, Yan Lu +13 more

MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer

Nature Communications(2025)10.1038/s41467-025-58524-9

N/A

0DataRank · unranked

12 citations

Ping Xie, Mary Hongying Cheng, Yueming Zhu, Xin Cui, Joshua Watson +19 more

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.08.002

N/A

0DataRank · unranked

5 citations

Jincong Q. Freeman, Sri G. Yarlagadda, Aishwarya Atmakuri, Kevin Kalinsky, Lajos Pusztai +5 more

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.03.462951

N/A

0DataRank · unranked

7 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +48 more

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial

UNC Libraries(2025)10.17615/dgtt-ap31

N/A

0DataRank · unranked

0 citations

Julie R. Gralow, Edith Perez, Kevin Kalinsky, Gabriel N. Hortobágyi, Nancy U. Lin +19 more

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.01.19.427299

N/A

0DataRank · unranked

0 citations

Jinfeng Chen, Patrick A. Cosgrove, Anne O’Dea, Priyanka Sharma, X. Cynthia +13 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0DataRank · unranked

335 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Kevin Kalinsky

Indexed papers

Top data-sharing exemplar

Papers